Cannabidiol
Cannabidiol, or CBD, is one of the most promising pharmaceutical compounds, as it’s non-psychoactive, and many studies have been conducted across many disease states, like multiple sclerosis. However, while most of the research has analyzed its anti-inflammatory properties, little is known regarding its antiviral activity. In some studies, researchers aimed to discover CBD’s potential therapeutic benefits against hepatitis C and B. They discovered that it reduced replication by over 80 percent in HCV.
The antiviral activity of cannabidiol against HCV indicates that it could be effective against autoimmune and viral hepatitis caused by macrophages and activated T cells. In addition, the study found CBD to reduce inflammation significantly for those with autoimmune HCV. However, it isn’t an accepted form of treatment yet for the condition, and it may come with some side effects if taken at the wrong dosage or when combined with other medications.
Therefore, it’s ill-advised to use cannabidiol-based products before speaking with a medical professional. Despite the favorable results studies have shown, there are still a lot of unknowns when it comes to CBD. More research is needed to determine how effective it is in treating the condition or if it can cause more complications.
